Our Science

Ibrexafungerp:
A novel antifungal

Ibrexafungerp is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

It has broad spectrum activity encompassing Candida, Aspergillus, Pneumocystis, Dimorphic fungi and mucorales, including multi-drug resistant (MDR) species and pan resistant species such as Candida auris. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).

Ibrexafungerp has the potential to be an essential therapy in the treatment of multiple serious fungal infections:

• Novel glucan synthase inhibitor
• Potent activity against most common fungi pathogens, including those resistant to other antifungals